[{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IXT-m200","moa":"Methamphetamine (Meth)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IXT-m200","moa":"Methamphetamine (Meth)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"IXT-m200","moa":"Methamphetamine (Meth)","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Kindolor Tosylate","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet, Enteric Coated","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Agreement","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Clear Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"SiteOne Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ST-2427","moa":"NaV1.7 channel","graph1":"Neurology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Enalare Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ENA-001","moa":"Potassium channel","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Stalicla","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Achieve Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"10","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Embera NeuroTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Stalicla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Lyndra Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Levomethadone","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"3-beta-(4-methoxybenzyloxy)pregn-5-en-20-one","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Omeros","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Funding","leadProduct":"OMS527","moa":"Phosphodiesterase 7 (PDE7)","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Omeros","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"OMS527","moa":"Phosphodiesterase 7 (PDE7)","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nafamostat","moa":"serine","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Powder in Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASP8062","moa":"GABAB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Promentis Pharmaceuticals | Altasciences Company Inc | Technical Resources International, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SXC-2023","moa":"Cystine\/glutamate transporter (SLC7A11)","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ Promentis Pharmaceuticals | Altasciences Company Inc | Technical Resources International, Inc.","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ Promentis Pharmaceuticals | Altasciences Company Inc | Technical Resources International, Inc."},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydrocodone Bitartrate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Camino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"SBP-9330","moa":"mGluR2","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"ASP8082","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Kinoxis Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"KNX100","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Intra-Cellular Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ITI-333","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Cerevel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CVL-354","moa":"Kappa opioid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Intra-Cellular Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ITI-333","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Intra-Cellular Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ITI-333","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Ensysce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Funding","leadProduct":"Oxycodone Prodrug","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"NYU Langone Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Funding","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Mebias Discovery","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"MEB-1170","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Caamtech","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"National Institute on Drug Abuse \/ Caamtech","highestDevelopmentStatusID":"1","companyTruncated":"National Institute on Drug Abuse \/ Caamtech"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"11","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection, Prolonged Release","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"11","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Cessation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Funding","leadProduct":"CSX-1004","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Naltrexone","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Subcutaneous Pellet","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual Film","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"7","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Phoenix Pharmalabs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone Analog","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Sublingual","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"11","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tempero Bio","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Clear Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etifoxine","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VK4-116","moa":"D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ Altasciences Company Inc","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ Altasciences Company Inc"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Implant","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Implant","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NRS-033","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Funding","leadProduct":"Cebranopadol","moa":"Opioid receptors; mu\/kappa\/delta | Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Implant","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Myosin Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"MT-110","moa":"T-cell surface glycoprotein CD3 epsilon (CD3E)","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"5","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"SiteOne Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"STC-004","moa":"NaV1.8 Channel","graph1":"Neurology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"BioCorRx","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral Implant","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"6","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Gilgamesh Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Ibogaine","moa":"Neuronal acetylcholine receptor alpha-2\/alpha-3 (CHRNA2\/A3)","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Copernicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"EpiVario","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"National Institute on Drug Abuse","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"National Institute on Drug Abuse","sponsor":"Proniras","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Tezampanel","moa":"Glutamate receptor ionotropic AMPA | Glutamate receptor ionotropic kainate","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"National Institute on Drug Abuse","amount2":0.01,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Drug Abuse \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"1","companyTruncated":"National Institute on Drug Abuse \/ National Institute on Drug Abuse"}]
Find Clinical Drug Pipeline Developments & Deals by National Institute on Drug Abuse
Details :
The grant will help support the initiation of a Phase 1 clinical trial to assess the safety, tolerability of MT-110, as a first-in-class treatment option for methamphetamine use disorder.
Details :
The funding aims to support the OMS527 is an orally bioavailable, small molecule antagonist of PDE7. It is being evaluated to treat Cocaine Use Disorder.
Details :
The net proceeds will fund longer toxicology studies and manufacturing of SBP-9330, a small molecule targeting mGlu2 receptor, to support planned Phase 2 trials for nicotine cessation.
Reset All
